Regeneron’s planned acquisition of 23andMe raises significant privacy concerns as experts warn about the lack of comprehensive federal regulations governing the transfer of genetic information.
Related Posts
Good news and bad news. The good news? We have…
The month of June is packed with blockbuster movies, and…
It will be nearly the end of the year before…